Cancel
David Proia
Biology and Drug Discovery
@
Acrivon Therapeutics
xh9wbl@138qk49.9qz
Sign up to see email
See Linkedin
Known information
- Has a Ph.D. in molecular and cellular biology from Baylor College of Medicine.
- Holds a B.S. in biochemistry from Worcester Polytechnic Institute.
- Previously served as VP of Oncology at ROME Therapeutics.
- Was the biology lead for the development of agents targeting an endogenous reverse transcriptase at ROME Therapeutics.
- Served as Senior Director of In Vivo Pharmacology at C4 Therapeutics.
- Was a project leader on multiple oncology programs, including CFT7455 (IKZF1/3 degrader), currently in clinical trials for patients with multiple myeloma and non-Hodgkin’s lymphoma.
- Previously held the position of Director of Cancer Biology and In Vivo Pharmacology at Synta Pharmaceuticals.
- Worked as a Scientist at AstraZeneca.
- Has contributed to projects advancing both early and later stage clinical development.
- Has over 40 peer-reviewed publications.
About Acrivon Therapeutics
Acrivon Therapeutics develops precision oncology medicines using a proprietary proteomics-based platform, with its lead candidate ACR-368 in a Phase 2 trial for multiple tumor types.
Report inaccurate information
